We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Analysis

Allergan IP Deal With Tribe Could Have Big Impact On PTAB

Law360, New York (September 15, 2017, 7:35 PM EDT) -- Allergan PLC's attempt to use a Native American tribe’s sovereign immunity to shield patents for its best-selling eye drug from inter partes review raises new questions for the Patent Trial and Appeal Board and concerns that similar deals could negatively impact the market for generic drugs.

The Irish drugmaker last week announced a deal where it sold patents for Restasis to the Saint Regis Mohawk Tribe, then licensed the patents back, in an attempt to use the tribe’s sovereign immunity to protect the patents from review...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.